Héctor Santana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Héctor Santana has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Yaima González
Pharmaceutical Technology Department, Center for Genetic Engineering and Biotechnology, PO Box 6162, Havana, Cuba
3 shared publicationsAlejandro Beldarraín
Central Office for Scientific Pole, 198th and 17, n° 1714, Cubanacan, Playa, Havana 11300, Cuba
2 shared publicationsOdalys Amarantes
Analytical Development Department, Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box. 6162, Havana 10600, Cuba
2 shared publicationsRolando Páez
Pharmaceutical Development Department, Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box. 6162, Havana 10600, Cuba
2 shared publicationsA. Beldarrain
Central Office for Scientific Pole, Havana, Cuba
1 shared publication- Albert Revuelta
Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), 08193 Bellaterra, Spain
1 shared publication
Latest Publications
- 6 March 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 21
In vivo evaluation of the antitumor peptide CIGB-552: antitumor activity, pharmacokinetics and safety of the subcutaneously administered peptide
Purpose The CIGB-552 peptide is a novel therapeutic alternative for the treatment of cancer. In this study, we aimed to determine the optimal formulation and route of administration for CIGB-552. Other objectives were to characterize the peptide’s pharmacokinetic profile in rats and conduct toxicity studies at different dosage regimens. Methods The antitumor activity of CIGB-552 was evaluated by different routes of administration (intraperitoneal, subcutaneous) and also with different peptide formulations (Tartrate/mannitol, Tartrate/trehalose) using a TC-1 tumor model in C57BL/6 mice. The pharmacokinetic profile of the peptide was also characterized after subcutaneous administration in Sprague-Dawley rats using PK Solver software. In addition, the safety of the peptide was evaluated following single-dose and repeated-dose administration schedules in healthy BALB/c mice. Results In the tumor model, subcutaneous administration of CIGB-552 and its tartrate/trehalose formulation resulted in a significant reduction in tumor volume compared to untreated groups. CIGB-552 exhibited a typical extravascular delivery profile, with rapid absorption, rapid tissue distribution, and rapid blood clearance. The peptide’s half-life was 2.5 h, and peak plasma concentration (Cmax) was reached in approximately 15 min. Furthermore, CIGB-552 was shown to have nonlinear pharmacokinetics across the evaluated dose and exposure range. On the other hand, CIGB-552 administration in the evaluated regimens was safe, with toxicity and fatal outcomes observed only with the 60 mg/kg dose administered subcutaneously every two days until seven doses were completed in total. Conclusions The peptide’s safety profile in repeated dosing, combined with evidence of no systemic accumulation, supports the development of new regimens involving higher and more frequent doses to enhance antitumor efficacy in clinical studies.
- 6 March 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 21
In vivo evaluation of the antitumor peptide CIGB-552: antitumor activity, pharmacokinetics and safety of the subcutaneously administered peptide
Purpose The CIGB-552 peptide is a novel therapeutic alternative for the treatment of cancer. In this study, we aimed to determine the optimal formulation and route of administration for CIGB-552. Other objectives were to characterize the peptide’s pharmacokinetic profile in rats and conduct toxicity studies at different dosage regimens. Methods The antitumor activity of CIGB-552 was evaluated by different routes of administration (intraperitoneal, subcutaneous) and also with different peptide formulations (Tartrate/mannitol, Tartrate/trehalose) using a TC-1 tumor model in C57BL/6 mice. The pharmacokinetic profile of the peptide was also characterized after subcutaneous administration in Sprague-Dawley rats using PK Solver software. In addition, the safety of the peptide was evaluated following single-dose and repeated-dose administration schedules in healthy BALB/c mice. Results In the tumor model, subcutaneous administration of CIGB-552 and its tartrate/trehalose formulation resulted in a significant reduction in tumor volume compared to untreated groups. CIGB-552 exhibited a typical extravascular delivery profile, with rapid absorption, rapid tissue distribution, and rapid blood clearance. The peptide’s half-life was 2.5 h, and peak plasma concentration (Cmax) was reached in approximately 15 min. Furthermore, CIGB-552 was shown to have nonlinear pharmacokinetics across the evaluated dose and exposure range. On the other hand, CIGB-552 administration in the evaluated regimens was safe, with toxicity and fatal outcomes observed only with the 60 mg/kg dose administered subcutaneously every two days until seven doses were completed in total. Conclusions The peptide’s safety profile in repeated dosing, combined with evidence of no systemic accumulation, supports the development of new regimens involving higher and more frequent doses to enhance antitumor efficacy in clinical studies.
- 22 September 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 222, 115070
Stability-indicative and conformation-specific enzyme linked immunosorbent assay for analysis of recombinant human gamma interferon
- 22 September 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 222, 115070
Stability-indicative and conformation-specific enzyme linked immunosorbent assay for analysis of recombinant human gamma interferon
- Open Access
- 15 January 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (1) , 199
DELOS Nanovesicles-Based Hydrogels: An Advanced Formulation for Topical Use
Topical delivery has received great attention due to its localized drug delivery, its patient compliance, and its low risk for side effects. Recent developments have focused on studying new drug delivery systems as a strategy for addressing the challenges of current topical treatments. Here we describe the advances on an innovative drug delivery platform called DELOS nanovesicles for topical drug delivery. Previously, the production of DELOS nanovesicles demonstrated potentiality for the topical treatment of complex wounds, achieving well-tolerated liquid dispersions by this route. Here, research efforts have been focused on designing these nanocarriers with the best skin tolerability to be applied even to damaged skin, and on exploring the feasibility of adapting the colloidal dispersions to a more suitable dosage form for topical application. Accordingly, these drug delivery systems have been efficiently evolved to a hydrogel using MethocelTM K4M, presenting proper stability and rheological properties. Further, the integrity of these nanocarriers when being gellified has been confirmed by cryo-transmission electron microscopy and by Förster resonance energy transfer analysis with fluorescent-labeled DELOS nanovesicles, which is a crucial characterization not widely reported in the literature. Additionally, in vitro experiments have shown that recombinant human Epidermal Growth Factor (rhEGF) protein integrated into gellified DELOS nanovesicles exhibits an enhanced bioactivity compared to the liquid form. Therefore, these studies suggest that such a drug delivery system is maintained unaltered when hydrogellified, becoming the DELOS nanovesicles-based hydrogels, an advanced formulation for topical use.
- 15 January 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (1) , 199
Open AccessDELOS Nanovesicles-Based Hydrogels: An Advanced Formulation for Topical Use
Topical delivery has received great attention due to its localized drug delivery, its patient compliance, and its low risk for side effects. Recent developments have focused on studying new drug delivery systems as a strategy for addressing the challenges of current topical treatments. Here we describe the advances on an innovative drug delivery platform called DELOS nanovesicles for topical drug delivery. Previously, the production of DELOS nanovesicles demonstrated potentiality for the topical treatment of complex wounds, achieving well-tolerated liquid dispersions by this route. Here, research efforts have been focused on designing these nanocarriers with the best skin tolerability to be applied even to damaged skin, and on exploring the feasibility of adapting the colloidal dispersions to a more suitable dosage form for topical application. Accordingly, these drug delivery systems have been efficiently evolved to a hydrogel using MethocelTM K4M, presenting proper stability and rheological properties. Further, the integrity of these nanocarriers when being gellified has been confirmed by cryo-transmission electron microscopy and by Förster resonance energy transfer analysis with fluorescent-labeled DELOS nanovesicles, which is a crucial characterization not widely reported in the literature. Additionally, in vitro experiments have shown that recombinant human Epidermal Growth Factor (rhEGF) protein integrated into gellified DELOS nanovesicles exhibits an enhanced bioactivity compared to the liquid form. Therefore, these studies suggest that such a drug delivery system is maintained unaltered when hydrogellified, becoming the DELOS nanovesicles-based hydrogels, an advanced formulation for topical use.
- 1 October 2017
- Published by Elsevier in Research in Veterinary Science
- Vol. 114, 502-510
The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552
- 1 October 2017
- Published by Elsevier in Research in Veterinary Science
- Vol. 114, 502-510
The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552
- Open Access
- 7 December 2016
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 17 (1) , 1-11
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. This could be achieved by combining IFN alpha and IFN gamma. The aim of this work was to characterize the pharmacokinetics and pharmacodynamics of a novel formulation containing a co-formulated combination of IFNs alpha-2b and gamma (CIGB-128-A). A group of nine healthy male subjects received intramuscularly 24.5 × 106 IU of CIGB-128-A. IFN concentrations were evaluated for 48 h. Serum neopterin, beta2-microglobulin (β2M) and 2′–5′ oligoadenylate synthetase (2′–5′ OAS), classical IFN-inducible serum markers, were measured during 192 h by enzyme immunoassay and body temperature was used as pharmacodynamic variable as well. Concerning pharmacokinetics, serum IFNs’ profiles were better fitted to a mono-compartmental model with consecutive zero order and first order absorption, one bioavailability value. No interferences by simultaneous administered IFNs were observed in their typical similar systemic profiles. Neopterin and β2M time profiles showed a delay that was efficiently linked to pharmacokinetics by means of a zero order absorption rate constant. Neopterin level was nine-fold higher than initial values, 48 h post-administration, an increment not described before. At this time, mean serum β2M peaked around the double from baseline. Serum concentrations of the enzyme 2′–5′ OAS was still elevated on the 8 day post-injection. The formulation was well tolerated. Most frequent adverse reactions were fever, headache, arthralgia and lymphopenia, mostly mild. The administration of co-formulated IFN alpha-2b and IFN gamma likely provides improved pharmacodynamic properties that may be beneficial to treat several malignancies. Cuban Public Registry of Clinical Trials RPCEC00000118 , May 24, 2011.
- 7 December 2016
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 17 (1) , 1-11
Open AccessPharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. This could be achieved by combining IFN alpha and IFN gamma. The aim of this work was to characterize the pharmacokinetics and pharmacodynamics of a novel formulation containing a co-formulated combination of IFNs alpha-2b and gamma (CIGB-128-A). A group of nine healthy male subjects received intramuscularly 24.5 × 106 IU of CIGB-128-A. IFN concentrations were evaluated for 48 h. Serum neopterin, beta2-microglobulin (β2M) and 2′–5′ oligoadenylate synthetase (2′–5′ OAS), classical IFN-inducible serum markers, were measured during 192 h by enzyme immunoassay and body temperature was used as pharmacodynamic variable as well. Concerning pharmacokinetics, serum IFNs’ profiles were better fitted to a mono-compartmental model with consecutive zero order and first order absorption, one bioavailability value. No interferences by simultaneous administered IFNs were observed in their typical similar systemic profiles. Neopterin and β2M time profiles showed a delay that was efficiently linked to pharmacokinetics by means of a zero order absorption rate constant. Neopterin level was nine-fold higher than initial values, 48 h post-administration, an increment not described before. At this time, mean serum β2M peaked around the double from baseline. Serum concentrations of the enzyme 2′–5′ OAS was still elevated on the 8 day post-injection. The formulation was well tolerated. Most frequent adverse reactions were fever, headache, arthralgia and lymphopenia, mostly mild. The administration of co-formulated IFN alpha-2b and IFN gamma likely provides improved pharmacodynamic properties that may be beneficial to treat several malignancies. Cuban Public Registry of Clinical Trials RPCEC00000118 , May 24, 2011.
- 1 May 2015
- Published by Parenteral Drug Association, Inc. in PDA Journal of Pharmaceutical Science and Technology
- Vol. 69 (3) , 399-416
Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing
We report on the stability assessment of a recombinant human epidermal growth factor (rhEGF) freeze-dried formulation for wound healing by intra-lesional injections. The suitability of packaging material for the light protection of finished dried powder was evaluated after stressed exposure conditions. Degradation kinetics of powder for injection was investigated at concentrations of 25–250 μg/vial and temperatures of 45, 60, and 70 °C. The long-term stability was evaluated after storage at 25 ± 2 °C/60 ± 5% relative humidity (6 months) and 2–8 °C (24 months) in the dark and analyzed at several time points. The stability after reconstitution with various diluents was also assessed after 24 h storage at 2–8 °C. The rhEGF samples were analyzed for structural integrity by reversed-phase high-performance liquid chromatography (RP-HPLC), size-exclusion HPLC, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Biological activity was investigated by measuring the cell proliferation in a murine fibroblast cell line. Results show that freeze-dried rhEGF in primary packaging only was photosensitive, as degradation by RP-HPLC that was completely suppressed by the secondary carton package was revealed. An increase in freeze-dried rhEGF stability was observed with the increase in protein concentration from 25 to 250 μg/vial. The long-term stability study showed no significant rhEGF degradation or physical change within the freeze-dried formulations containing 25 or 250 μg/vial of rhEGF. No physical, chemical or biological changes were observed for rhEGF after reconstitution in water for injection or 0.9% sodium chloride during the storage conditions studied.
- 1 May 2015
- Published by Parenteral Drug Association, Inc. in PDA Journal of Pharmaceutical Science and Technology
- Vol. 69 (3) , 399-416
Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing
We report on the stability assessment of a recombinant human epidermal growth factor (rhEGF) freeze-dried formulation for wound healing by intra-lesional injections. The suitability of packaging material for the light protection of finished dried powder was evaluated after stressed exposure conditions. Degradation kinetics of powder for injection was investigated at concentrations of 25–250 μg/vial and temperatures of 45, 60, and 70 °C. The long-term stability was evaluated after storage at 25 ± 2 °C/60 ± 5% relative humidity (6 months) and 2–8 °C (24 months) in the dark and analyzed at several time points. The stability after reconstitution with various diluents was also assessed after 24 h storage at 2–8 °C. The rhEGF samples were analyzed for structural integrity by reversed-phase high-performance liquid chromatography (RP-HPLC), size-exclusion HPLC, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Biological activity was investigated by measuring the cell proliferation in a murine fibroblast cell line. Results show that freeze-dried rhEGF in primary packaging only was photosensitive, as degradation by RP-HPLC that was completely suppressed by the secondary carton package was revealed. An increase in freeze-dried rhEGF stability was observed with the increase in protein concentration from 25 to 250 μg/vial. The long-term stability study showed no significant rhEGF degradation or physical change within the freeze-dried formulations containing 25 or 250 μg/vial of rhEGF. No physical, chemical or biological changes were observed for rhEGF after reconstitution in water for injection or 0.9% sodium chloride during the storage conditions studied.
- 1 November 2014
- Published by Elsevier in Biologicals
- Vol. 42 (6) , 322-333
Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying
- 1 November 2014
- Published by Elsevier in Biologicals
- Vol. 42 (6) , 322-333
Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying
- 1 August 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 452 (1-2) , 52-62
Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: Effect of pH, buffers, and excipients
- 1 August 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 452 (1-2) , 52-62
Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: Effect of pH, buffers, and excipients